Victor G. Kramer

574 total citations
17 papers, 433 citations indexed

About

Victor G. Kramer is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Victor G. Kramer has authored 17 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Virology, 13 papers in Infectious Diseases and 6 papers in Epidemiology. Recurrent topics in Victor G. Kramer's work include HIV Research and Treatment (14 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Victor G. Kramer is often cited by papers focused on HIV Research and Treatment (14 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Victor G. Kramer collaborates with scholars based in Canada, United States and China. Victor G. Kramer's co-authors include Ruth M. Ruprecht, Nagadenahalli B. Siddappa, Xinyong Liu, Peng Zhan, Siddappa N. Byrareddy, Vigneshwaran Namasivayam, Sonali Kurup, Murugesan Vanangamudi, Jacob Kongsted and Francis J. Novembre and has published in prestigious journals such as PLoS ONE, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Victor G. Kramer

16 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Victor G. Kramer Canada 10 321 245 117 110 69 17 433
Darren Jardine Australia 10 238 0.7× 219 0.9× 107 0.9× 78 0.7× 76 1.1× 17 436
C. M. Nielsen Denmark 9 213 0.7× 143 0.6× 118 1.0× 89 0.8× 80 1.2× 16 364
Wendeline Wagner United States 7 259 0.8× 194 0.8× 69 0.6× 125 1.1× 67 1.0× 8 379
Aletta Kliphuis Netherlands 9 401 1.2× 259 1.1× 69 0.6× 105 1.0× 113 1.6× 12 432
Beata Nowicka-Sans United States 11 297 0.9× 307 1.3× 72 0.6× 47 0.4× 86 1.2× 11 423
Debra P. Merrill United States 12 573 1.8× 558 2.3× 132 1.1× 94 0.9× 89 1.3× 16 742
Jason Isaacson United States 6 317 1.0× 269 1.1× 58 0.5× 40 0.4× 108 1.6× 6 376
Brett S. Robinson United States 6 424 1.3× 445 1.8× 57 0.5× 61 0.6× 169 2.4× 9 633
Anastasia Selyutina United States 11 246 0.8× 160 0.7× 67 0.6× 86 0.8× 187 2.7× 18 427
Cindy Buffone United States 12 383 1.2× 275 1.1× 122 1.0× 156 1.4× 225 3.3× 16 607

Countries citing papers authored by Victor G. Kramer

Since Specialization
Citations

This map shows the geographic impact of Victor G. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor G. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor G. Kramer more than expected).

Fields of papers citing papers by Victor G. Kramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor G. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor G. Kramer. The network helps show where Victor G. Kramer may publish in the future.

Co-authorship network of co-authors of Victor G. Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Victor G. Kramer. A scholar is included among the top collaborators of Victor G. Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor G. Kramer. Victor G. Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Namasivayam, Vigneshwaran, Murugesan Vanangamudi, Victor G. Kramer, et al.. (2018). The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. Journal of Medicinal Chemistry. 62(10). 4851–4883. 146 indexed citations
2.
Han, Ying-Shan, Wei‐Lie Xiao, Hongtao Xu, et al.. (2015). Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor. Antiviral chemistry & chemotherapy. 24(1). 28–38. 8 indexed citations
3.
Kramer, Victor G. & Mark A. Wainberg. (2015). Resistance Against Inhibitors of HIV-1 Entry into Target Cells. Future Virology. 10(2). 97–112.
4.
Kramer, Victor G., Said Hassounah, Susan P. Colby-Germinario, et al.. (2014). The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. Journal of Antimicrobial Chemotherapy. 70(3). 750–756. 9 indexed citations
5.
Kramer, Victor G., et al.. (2014). Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc. Journal of the International AIDS Society. 17(4S3). 19531–19531. 4 indexed citations
6.
Quan, Yudong, Hongtao Xu, Victor G. Kramer, et al.. (2014). Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines. Virology Journal. 11(1). 177–177. 4 indexed citations
7.
Kramer, Victor G., et al.. (2014). Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal Antibodies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(1). 7–14. 5 indexed citations
8.
Siddappa, Nagadenahalli B., Victor G. Kramer, Sandra J. Lee, et al.. (2013). Live Attenuated Rev-Independent Nef¯SIV Enhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques. PLoS ONE. 8(9). e75556–e75556. 7 indexed citations
9.
McCallum, Matthew, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, et al.. (2013). Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy. 57(10). 4681–4688. 20 indexed citations
10.
Kramer, Victor G., Susan M. Schader, Maureen Oliveira, et al.. (2012). Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load. Antimicrobial Agents and Chemotherapy. 56(8). 4154–4160. 23 indexed citations
11.
Siddappa, Nagadenahalli B., Jennifer Watkins, Klemens J. Wassermann, et al.. (2010). R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models. PLoS ONE. 5(7). e11689–e11689. 35 indexed citations
12.
Chénine, Agnès L., Nagadenahalli B. Siddappa, Victor G. Kramer, et al.. (2010). Relative Transmissibility of an R5 Clade C Simian‐Human Immunodeficiency Virus Across Different Mucosae in Macaques Parallels the Relative Risks of Sexual HIV‐1 Transmission in Humans via Different Routes. The Journal of Infectious Diseases. 201(8). 1155–1163. 43 indexed citations
13.
Mirshahidi, Saied, Victor G. Kramer, James B. Whitney, et al.. (2009). Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival. Vaccine. 27(12). 1825–1833. 18 indexed citations
14.
Siddappa, Nagadenahalli B., Ruijiang Song, Victor G. Kramer, et al.. (2008). Neutralization-Sensitive R5-Tropic Simian-Human Immunodeficiency Virus SHIV-2873Nip, Which Carries env Isolated from an Infant with a Recent HIV Clade C Infection. Journal of Virology. 83(3). 1422–1432. 32 indexed citations
15.
Humbert, Michael, Robert A. Rasmussen, Ruijiang Song, et al.. (2008). SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology. 5(1). 94–94. 53 indexed citations
16.
Siddappa, Nagadenahalli B., Ruijiang Song, Victor G. Kramer, et al.. (2008). Neutralization-Sensitive R5 SHIV-2873Nip Encoding env from a Infant with Recent HIV Clade C Infection. 1 indexed citations
17.
Kramer, Victor G., Nagadenahalli B. Siddappa, & Ruth M. Ruprecht. (2007). Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes. Current HIV Research. 5(6). 642–655. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darren Jardine Breakdown of academic impact, for papers by C. M. Nielsen Breakdown of academic impact, for papers by Wendeline Wagner Breakdown of academic impact, for papers by Aletta Kliphuis Breakdown of academic impact, for papers by Beata Nowicka-Sans Breakdown of academic impact, for papers by Debra P. Merrill Breakdown of academic impact, for papers by Jason Isaacson Breakdown of academic impact, for papers by Brett S. Robinson Breakdown of academic impact, for papers by Anastasia Selyutina Breakdown of academic impact, for papers by Cindy Buffone
Rankless by CCL
2026